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The most important recent advance in th e
med ical management of patients with acute and
ch ronic congestive heart failure has been the
application of system ic vasod ilator drugs to reduce ventricu lar afterload, thereby improvin g
low cardi ac output and decreasing increased
venous pressure. Although such drugs have
been employed fo r several years to treat essenti al hypertension, hypertensive heart failure ,
acute hypertensive crises , and angina pectoris ,
only in the past five years has their use become
wid ely popular in the therapy of normotensive
heart failure. 1 While it can be reasoned th at the
vasodilator approach is a log ical therapeutic extension of fundamenta l determinants regulating
cardiac funct ion known for many years, it is
nevertheless intriguing that consideration has
been delayed until the present time of such a
useful concept as afterl oad reduction th erapy in
heart failure.

Regulation of Cardiac Function
Th e intact heart is normally govern ed by th e
intimate integration of four prin cipal determinants regu latin g stroke volume and cardi ac output (Fig 1 ): 1) preload (ventricular end-d iastolic
volume} , 2) contractility (variable force of ventricul ar contraction independent of load ing}, 3)
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aft erlo ad (ventricular systo li c tension during
ejection} , and 4) heart rate. 2 Th e terms " cardi ac
funct ion " and " ventri c ular performance " are
used in the general sense to refer to the combined action of these four determinants of cardiac output, and not necessarily to the singl e
determinant of cont ract ilit y. The disturbed
mec han isms operative in all types of clinical
heart disease can be eva luated and accu rately
measured within the framework of isolated or
composite disorders of these fou r maior determinants of cardi ac performance 3 Besides affording a better understanding of the manner in
whi ch va ri ous types of heart disease lead to disturbed pump performance , appreciation of th e
determinants of cardiac function (Fig 1) provides the rationale for an org ani zed approach to
the integ ration of therapy in the management of
congestive heart failure. 4

Rationale of Afterload Reduction Therapy
Facilitation of ventricular emptyin g lead in g to
increasing lowered stroke volum e is th e fundamental objective of therapy for heart failure.
Conventional treatmen t of congestive heart failure has focused primarily on increasing ventri c ul a r strok e vo lum e and ca rdi ac output
through the use of direct pos itive in otrop ic
agents and concom itant diuretic therapy. In th e
case of patients with coronary heart disease in
wh om ac ute and chronic pump failure results
principally from the impairment and loss of myocardi al con tractil e units, an increase in th e inotropic state of th e remaining functioning heart
musc le may insufficiently augment cardi ac per-

formance. Th e powerful inotropic stimulus of
cardiotonic agents may also increase overall
myocardi al oxygen demand (M\/0 2 ) , whi ch is
potentially detrimental in acute ischemic heart
disease. In contrast to elevating low stroke output by direct inotropic stimu lation in heart failure , reducing impedance to left ventricu lar ejecti on by administrati on of systemi c arteriolar
dilator drug s provides a uniqu e th erapeutic
mechanism for the augmentation of pump performan ce by increasing ventricular emptying ,
while also dimin ishing M\/0 2 . 5

Determinants of Ventricular Afterload
As with ventri cular filling (preload) , several
factors influence afterload and impedance to
left ventricu lar outflow. The load or ten sion that
the left ventri cle must develop to e1ect stroke
volum e constitutes ventri cular afterload . Afterload is defined as th e wall tension during left
ventricular ejection 5 The two principal determinants of afterload are systoli c pressure and
radiu s of the ventric le, according to the Laplace
formu la. In turn , systolic pressure is related to
impedance to blood flow in th e aorta , and the
radius of the ventricular chamber is related to
left ventricular volume (preload) .
Determinants of Aortic Impedance
Impedance to left ventri cular ejection is the
in stantan eo us relation between th e rate of
change in aortic pressure and aorti c flow .5 Left
ventricular outflow impedance is governed primarily by two factors 1) th e compliance (relation of pressure to fl ow) in the large arteries ; and
2) the total peripheral vascu lar resistance (the
rate of run off from the systemi c arterial tree)
which is determined principally by the radius or
cross-sectional area of the systemic arteriolar
beds . Of these factors reg ulating impedance ,
system ic arteriolar resistance is th e most important and th e vari able most subject to modifi cation by pharmacologic vasodilation .
Determinants of Left Ventricular Energetics
In the setting of impaired ventricu lar performance, elevation of outflow impedance results in
declines of the extent and rate of fiber shortening and reduction in the ejection fraction with
the consequent elevation of left ventricular filling
pressure (preload). Thus stroke volume must be
maintained at increased energy costs related to
the increase in intramyocardial wall tension (af-
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Fig 1-Representation of the fou r principal determinants of
cardiac output

terload) (Fi g 2). 5 In severe pump fai lure, elevations of impedance and preload (afterload product), whi ch are inherent consequences of the
heart failu re state, result in the ri se of M\/0 2 .
Thi s ri se in M\/0 ? leads to potential myocardial
isc hemia and continued impairment of pump
function , ca using greater sympatheti c-induced
ri se of peripheral vascu lar resistance with resultant in creases in ventricular afterl oad and preload. Thus a prog ressively deleterious cycle adversely affectin g M\/0 2 and pump performance
is set in motion by th e ope ration of co mpensatory mechanisms attempting to maintain
cardi oc ircu latory integ rity. Systemic vasodi lator
th erapy, whi ch produces red uctions in both impedance and preload , interrupts th is harmfu l
chain of events whi le augmenting cardiac output , diminishing pu lmonary congestion and improving myocardial energeti cs. 5

Clinical Use of Systemic Vasodilators
Whil e it has been two decades since
Burch produced gang lionic blockade with the
intravenous vasod ilator, hexamethonium , in the
relief of intractable pu lmonary congesti on due
to left heart failure6 and John son diminished
acute pulmonary edema by sublingual nitroglycerin in left ven tri cul ar dysfunction ,1 the expressed purpose of those two isolated reports
was clearl y the reducti on of increased left ventri cular preload and elevated system ic venous
ton e in th e amelioration of backward fa ilure (pulmonary congestion) via periphera l venodilation
Th at vasod ilators might be useful in decreasing
raised periph eral arteri al resistance to diminish

WALL TENSION--IMV?2I-- HEART RATE
CONTRACTILITY
FIG 2-Representati on of the three major determinants of
myocardial oxygen consumption (M\/0 2 ) lntramyocardi al
systolic wa ll tension is left ventricular afterload which is a
product of preload (left ven tricular volu me) and impedance
(systolic blood pressure)
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Normal

Ventricular preload

fl G 3 -Ventricular func ti on curves relatin g ve ntricular performance (cardiac output) to ventricular preload (ventri cular
end-diastolic pressure). Curve 1 represents increased ca rdiac contractility, while curves 0 1 and 0 2 indicate progressively severe reduct ions in contractility.

pump outflow impedance with improvement in
forward failure (low cardiac output) was not appreciated at that time .
The pharmacologic approach of vasodi lator therapy for impedance reduction was first
employed c lini ca ll y in norm otensive severe
heart failure by MaJid and associates in 1971 .8
Thus , infusion of the alpha-adrenergic blocking

"'c:
"'
E
CJ

0

t:

o,

"'
.;

Q.

:;
CJ

·sc:

o,

>"'
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FIG 4- Ventri cular fun ction curves relatin g ventricular performan ce (cardi ac output) to th e aortic impedance component (total systemic vasc ular resistance) of ventricular afterload Thi s relati onship beco mes in c reas in gly stee p
(greater depressio n of cardi ac output) as ventricular fun cti on
declines from th e normal curve to the curves O 1 , 0 2 and 0 3
indicating progressively grea ter depression of ca rdi ac contractility . As cardi ac dysfun ction worsens, th e point of ventricular functi on (closed circles) of the progressively failing
ventric le on the spectrum of curves shifts to a higher impedance component of afterl oad .
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agent , phentolamine , in acute myocardial infarction was observed to result in the decline of
elevated systemic vascu lar resistance , accompanied by the rise of low cardiac output and the
fall of elevated pulmonary artery pressure, without substantial alterations in systemic arterial
pressure and heart rate . The modern era of afterload reduction gained momentum following
reports of simi lar hemodynamic benefits
achieved by intravenous nitroprusside in acute
myocardial infarction patients 9 - 11 The vasodi lator concept spread rapidly and has now been
extended to the management of severe chronic
cardiac dysfunction of various types 5 12 - 18
As to why the idea of afterload reduction
therapy of heart fai lure was not recognized
sooner, it seems to me that this delay has been
largely the result of a lack of understanding , until recently , of the critical relationships between
peripheral circu latory dynamics and cardiac
performance 19 Furthermore , the relation of cardiac output to peripheral vascu lar activity is dependent upon left ventricu lar contractility When
the heart is normal , cardiac output is principally
governed by systemic venous tone with the left
ventricle operating on the steep ascending limb
of its Frank-Starling curve (outflow-preload relation) (Fig 3 ); aortic impedance reduction is of
littl e importance. In contrast, in the presence of
left ventricu lar dysfunction , arterial resistance is
elevated and cardiac output becomes strong ly
dependent on outflow resistance (Fig 4) Thus ,
the interplay between impedance (arterial resistance bed) and preload (venous capacitance
bed) reductions is that preload is more important than impedance in the normal heart (cardiac output declines) (Fig 3) , while in the failing
heart , impedance reduction predominates over
preload decline (cardiac output rises) (Fig 4)
While profound peripheral arteria l and
venous constriction accompanies chronic heart
failure ,2 only recently has it become appreciated that the heightened adrenergic activity in
response to lowered cardiac output , while
seeming ly useful in maintaining blood pressure,
may result in a greater level of increased systemic vascu lar resistance than is required to
sustain arterial pressure, and thus this reflex
adaptive mechanism may actually further decrease cardiac output (Fig 4) 1 A harmful cyc le
is thereby provoked in which the heart failure
patient reaches a greater depression of hemodynamics than is really optimal, system ic vascu-

lar resistance being higher and cardiac output
lower than are salutary . In addition , systemic
venoconstriction may also become excessive in
chronic heart failure. Consequently, there occurs greater elevation of left ventricular enddiastolic pressure than is required relative to the
lowered cardiac output on the depressed and
flattened ventricu lar function curve characteristic of impaired contractility. Importantly , vasodilator therapy possesses the ability to interrupt
thi s deleterious sequence of events by partially
counteracting th e compensatory sympathetic
reflex mechanism. '

Spectrum of Systemic Vasodilator Drugs
A vari ety of intravenous, oral , sublingual
and cutaneous agents are now readily available
which provide a spectrum of acti ons which result in the elevation of lowered card iac output
by reducing peripheral vascu lar resistance and/
or decline of increased ventricular end-diastolic
volume (ventricular preload) by lowering venous
tone. These drugs produce disparate modifications of cardi ac function by their differing alterations of preload versus impedance, which are
dependent upon their relative effects on systemic arteriolar resistance and venous capaci~
tance vessels characteristic of each agent (Fig
5) 2 0 In addition, these drugs cause concomitant
reduction in M\/0 2 which is of special importance in ischemic heart disease.
Therefore, modulation of card iac function
by the vasod ilators is determined by their relative preload and impedance effects (Fig 6).
Thu s, the nitrates 15 principally cause venod ilation (decrease elevated left ventricular end-diastol ic pressure); nitroprusside, 2 ' phentolam ine, 2 0
and prazosin 2 1 produce balanced arterial and
venous dilation (decrease elevated left ventricular end-diastolic pressure and inc rease lowered
cardiac output) provided left ventricular filling
pressure is maintained at th e upper limit of normal' ?; while hydralazine ' 3 predominantly effects
arteriolar dilation (increases lowered cardiac
output). With depressed cardiac output plus
highly elevated left ventricular end-d iastolic
pressure and elevated peripheral vascular resistance, nitrates' b also ach ieve some increase of
lowered cardiac output by markedly reducing
increased peripheral vascular resistance. Combined nitropru sside and dopamine 22 or dobutamine synergistically increase low cardiac output
and decrease raised left ventricular end-dias-
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FIG 5-Diagram of the spectrum of actions of systemic
vasodilators on the peripheral arterial tree and systemic
venous bed. CO = cardiac output ; EDP = left ventricular
end-diastolic pr~ssure; LVEDV = left ventricular end-diastolic volume; MV0 2 = myocardial oxygen consumption; IV
= intravenous; SL = sublingual; H = hydralazine.
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LVEDP(mm Hg)
FIG 6-Relationship between card iac output (CO) and left
ventricular end-diastolic pressure (LVEDP) in a normal subject (left curve) and a patient with congestive heart fa ilure
(CHF) (right curve) Point A indicates the point of operation
of the dysfunctioning left ventricle in CHF. The intermediate
curve ( 1) is the improved relation between CO and LVEDP
after the administration of digitalis (Point E), nitroprusside
(NP) to above LVEDP of 12 mm Hg (Point B), and NP to below LVEDP of 12 mm Hg (Point C) with the addition of dextran (Point B). Prazosin and combined hydralazine-nitrate
therapy are the same as NP from Point A to Point B. The enhanced CO and reduced LVEDP fol lowing the administration of phentolamine (PT) are shown by Point F. Hydralazine
therapy can be represented from Point A to Point E. It is instructive that the improvements from Point A on the lowest
ventricular function curve to Point B on the intermediate
function curve (1) after NP administration and to Point F after PT was given are not th e result of increased contractility;
rather, they are due to the en hanced relation between CO
and LVEDP that the reduction of impedance to left ventricular ejection NP and PT allow. Point D on the CHF curve is
the LVEDP after diuretic or nitrate therapy. The intermediate
curve (2) demonstrates the improvement in CO and decrease of LVEDP achieved with combined NP and dopamine therapy (Point G) The horizon tal broken line indicates
the lower limit of normal for CO and the vertical broken line
indicates the upper limit of normal of LVEDP. Congestion =
pulmonary congestion.
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tolic pressure. Mechanical coun terpu lsation
aid s nitroprussid e in acute myocardial infarction. The 30-minute venodilator action of
sublingual nitroglycerin ?3 ? 4 is extended by 4 to
6 hours by cu taneous nitroglycerin ointment, 20
oral isosorbide dinitrate, 10 oral pentaerythritol
tetranitrate / 6 and by sustained-release nitroglycerin capsu les. ?1 Ambu latory oral vasodilator
therapy is provided by long -acti ng nitrates' 0 (relieve pulmonary congestion) ; hydralazine ' 3 (improves fatigue) ; and prazosin alone, ' 5 ·? 8 combined nitrate-hydralazine / 9 and comb in ed
prazosin-hydralazine" (improve both dyspnea
and fatigue).

Conclusions and Future Directions
Since activi ty of the renin-angiotensin system is increased in cardi ac dysfunction .2 ang iotension II con tributes in part to the increase of
total peripheral vascular resistance characteristic of the heart fa ilure state. Furthermore , this
ren in mechanism is st imul ated in most instances of chron ic systemic vasod il ator th erapy
wh ich attenuates systemic arteri olod ilation produced by such treatment. Because recent evidence has been provided that admin istration of
angiotensin-converting enzyme inhibitor in patients with heart fa ilure resu lts in dilation of the
peripheral arteri al bed with an increase in cardiac output and decrease in left ven tri cu lar filling pressure , considerable attent ion is now
being focused on the eff icacy of oral and intravenous convertin g enzyme inhibitors alone and
in combinati on with conventional system ic vasodilators in c li nical heart failure. 30 In add iti on , the
vasodilator properties of the prostaglandins are
also under evaluation in heart failure therapy .
The initial adm inistration of the vasodilators to congestive heart failure patients is usually accompanied by a favorable diuresis. However , with prolonged use of the agents, body
fluid accumu lation often takes place, requi ring
greater dosage of concom itant diuretics. Whil e
oral furosemide is generally useful in this respect , the administration of spironolactone has
been particularly beneficial in effecting diuresis,3 ' probably caused by vasodi lator-stimulation of the renin axis , resulting in increased aldosterone secretion.
With the prolonged use of each of th e oral
vasodilators in the ambu latory treatment of severe congestive heart failure , tolerance to the
agents may develop in some individuals after
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several months. In the case of prazosin, tolerance can occu r in approximately one third of
patients after six months of effective therapy 32
This tolerance is surmountable with a return of
prazosin efficacy by increasing the dose of the
drug, or by the brief discontinuation of the agent
for a few weeks , or by switching for a short period to another vasodilator regimen suc h as
trimazosin 33 or comb in ed nitrate-hydralazine
Not a single instance of tachyphylaxis with repeated prazosin adm inistration has been observed in ove r 1 50 heart failure patients to
whom the agent has been given for either investigational or therapeutic purposes at ou r inst itution . The few reports of appa ren t prazosin
tachyphylaxsis can each be read ily attributed to
fa ulty study design and/or in correct interpretation suc h as those by Chatterjee ,3 4 Packer
et al,34 and Elkayam et al. 36 In contrast , the
chron ic use of hydralazin e in heart fa ilure, besides possible tolerance and the occasional
side effects of the lupus erythematosus syndrome and peripheral neuropathy, may cause
hydralaz in e- indu ced tachycardia , a frequent
and seri ous comp lication ,3 1 lead ing to potentially lethal dysrhythmias , angina pectoris, and
left ventricular pump deterioration.
Th e most important question as yet unanswered is the effectiveness of vasodi lator therapy in ac ute and chron ic refractory heart failure
and in reducing comp li cations and mortality. Although some prelimin ary studi es have been encouraging , th e definitive answers have not yet
been established If myocardial ischem ia plays
an important role in essential hypertension, cardiomyopathies and chron ic coronary heart disease, then the in creased ventricular filling pressures in these cond itions probably con tribute to
sustained subendocard ial ischemia with resu ltant progression of cardi ac dysfunction ' Provided this mechanism is operative , then reduction of increased filling pressure by vasod ilators
should improve subendocardi al perfusion and
thereby diminish morbidity and extend longevity
It is rema rk ab le how quickly system ic
vasodilator therapy has become established as
an important new medical treatment for both
acute and chron ic heart failure. ' 9 Perhaps no
other recent therapeutic concept in cardi ovascular medicine has been so rapidl y translated
into practical clinical management as that of reducing left ventricular afterload by means of

vasodilator drugs. In our thinking about the
management of congestive heart failure, it is apparent that a change of focus has occurred
from emphasis on contractility prevalent in the
past decade to innovative considerations of cardiac unloading by agents that primarily relax
vascular smooth muscle without direct actions
on the heart. 1 In consort, reexamination of the
proper role of the digitalis glycosides is taking
place.
Some clinicians maintain that the vasodilators are important as adjuncts in severe heart
failure for use wh en traditional means are inadequate , to be added only in combination with
digitalis and diuretics; others already view the
vasod ilators as equal or even better alternatives
than the conventional agents. In the difficult circumstance of refractory acute or chronic heart
failure , the combination ' of vasodilators and
powerful cardiotonics such as dopamine (Fig 6)
or dobutamine in hospital situations, ~2 and digitalis38 or promising new oral positive inotropics
on the horizon in outpatient settings, 1 provide
the most potent pharmacologic augmentation of
pump function possible. It is probable in the future th at as more experience is gained with the
vasodilators and as newer agents become available , the systemic vasodilators will be utilized as
frequently as digitalis in the standard treatment
of congestive heart failure .
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